Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Related Content:

Melanoma

FDA Grants Fast Track Designation to Pembrolizumab Plus Personalized Immunotherapy for Metastatic Melanoma

Omid Hamid, MD, on Trailblazing Research in Melanoma

Adjuvant Pembrolizumab Improves Quality-of-Life Vs Interferon α or Ipilimumab in Resected Melanoma